Actively Recruiting
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
Led by University of Alabama at Birmingham · Updated on 2025-12-12
132
Participants Needed
2
Research Sites
224 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.
CONDITIONS
Official Title
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women
- Gestational age between 23 weeks, 0 days and 35 weeks, 6 days
- Diagnosis of hypertensive disorder of pregnancy including gestational hypertension or preeclampsia without severe features
- No evidence of severe preeclampsia features at enrollment
- No current need for delivery
- Planned expectant management at enrollment
- Singleton or dichorionic twin pregnancy defined at or beyond 14 weeks gestation
- Intact membranes
You will not qualify if you...
- Preeclampsia with severe features, including systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg on two occasions at least 4 hours apart unless treated earlier
- Thrombocytopenia with platelets lower than 100 x 10e9/L
- Impaired liver function with elevated liver enzymes or severe persistent right upper quadrant or epigastric pain
- Renal insufficiency with serum creatinine >1.1 mg/dL or doubling without other renal disease
- Pulmonary edema
- New-onset headache unresponsive to medication
- Visual disturbances
- Renal dysfunction before 20 weeks gestation with creatinine ≥1.2 mg/dL or proteinuria ≥300 mg/24 hours, protein/creatinine ratio ≥0.3, or urine dipstick ≥2 without infection
- Stage 2 chronic hypertension
- Contraindications to labetalol or nifedipine XL
- Unable or unwilling to follow management recommendations
- Fetal growth restriction below 10th percentile within 3 weeks prior
- Oligohydramnios with amniotic fluid pocket <2 cm within 48 hours prior
- Known major structural or chromosomal fetal abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
Oschner
New Orleans, Louisiana, United States, 70115
Actively Recruiting
Research Team
R
Rachel Sinkey, MD
CONTACT
A
Alan Tita, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here